Entrada Therapeutics (TRDA) said Monday that the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD.
The company said the 1b study is designed to evaluate ENTR-601-44's safety and tolerability in about 32 adults with DMD who are exon-44 skipping amenable.
Shares of Entrada Therapeutics were up more than 9% in recent premarket activity Monday.
Price: 14.28, Change: +1.24, Percent Change: +9.51
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。